Search

Reactive oxygen species (ROS), including superoxide anion, are involved in regulating various signaling pathways and are also responsible for oxidative stress. Sensing superoxide anion is of particular importance due to its biological significance. One potential approach is to use Coelenterazine as a chemiluminescent probe for the dynamic sensing of this ROS. In this study, we investigated the superoxide anion-triggered chemiluminescence of native Coelenterazine and two halogenated analogs and found that they showed a ~100-fold enhancement of light emission in aqueous solution, which was significantly reduced in methanol and nonexistent in aprotic solvents. In fact, Coelenterazine showed more intense light emission in aprotic solvents and, interestingly, although the light emission of the analogs seemed relatively unaffected by the solvents, their chemiluminescence was significantly quenched in water compared to methanol and, especially, to aprotic media. This suggests that the quenching effect observed for Coelenterazine is responsible for the differences in aqueous media, rather than an intrinsic enhanced emission by the analogs. In summary, we present Coelenterazine analogs that could serve as a basis for enhanced sensing of superoxide anion, providing information that could further our understanding of this chemiluminescent system. [ABSTRACT FROM AUTHOR]

Photodynamic therapy (PDT) of cancer possesses advantageous features, such as a minimally invasive nature and few side-effect [1]. However, its use can be restricted to more surface tumors, due to its dependance on light-irradiation. To overcome this problem, we propose the development of single-molecule photosensitizers (PSs), based on chemiluminescent (CL) marine Coelenterazine (Clz) [2-6], which can be self-activated in the absence of light. Clz analogs were synthesized via routes optimized by our team [2-6], and their structure was characterized by HR-MS, NMR and FTIR spectroscopy. They were subjected to a through luminometric and photophysical characterization, to determine their CL features and singlet oxygen sensitization [2-6]. Their toxicity was investigated in vitro toward different cancer (breast, prostate, neuroblastoma, lung and gastric) and noncancer (breast and keratinocytes) cell lines, via the MTT assay in the absence of light [2-6]. The obtained Clz analogs were designed so their CL reaction generate mainly triplet states, instead of singlet excited ones [2-6]. They were shown to indeed be able to sensitize the highly cytotoxic singlet oxygen, without light-irradiation, due to a CL reaction triggered solely by molecule overexpressed in cancer cells (superoxide anion) [2-6]. In vitro assays showed that these analogs present cytotoxicity toward all the different studied cancer cell lines [2-6]. Moreover, some of them even showed comparable or even better activity than a reference chemotherapeutic drug [3,4]. Finally, a promising profile of safety was observed in testing with noncancer cells [3]. Different single-molecule PSs were developed, which are capable of intracellular self-activation without light-irradiation [2-6]. Namely, they are directly chemiexcited to triplet excited states via a CL reaction triggered by a molecule overexpressed in cancer cells, which generates singlet oxygen without light-irradiation. This new approach was found to induce toxicity toward different cancer cell lines, while possessing a promising profile of safety for noncancer cells. Thus, these PSs can provide a pathway for eliminating the light-related restrictions of PDT, while maintaining its advantages. [ABSTRACT FROM AUTHOR]